(VIANEWS) - Sunstone Hotel Investors Sunstone Hotel Investors (SHO), Globus Medical (GMED), Yelp (YELP) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Sunstone Hotel Investors Sunstone Hotel Investors (SHO)
30.3% sales growth and 10.06% return on equity
Sunstone Hotel Investors, Inc., a lodging real-estate investment trust ("REIT"), has interest in 19 hotels with 9,997 rooms. Sunstone is a company that acquires, manages, assets, renovates, or repositions hotels that are considered long-term relevant real estateA(r). Most of these hotels are owned by nationally recognized brands like Marriott, Hilton, and Hyatt.
Earnings Per Share
As for profitability, Sunstone Hotel Investors Sunstone Hotel Investors has a trailing twelve months EPS of $0.91.
PE Ratio
Sunstone Hotel Investors Sunstone Hotel Investors has a trailing twelve months price to earnings ratio of 10.59. Meaning, the purchaser of the share is investing $10.59 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.06%.Sales Growth
Sunstone Hotel Investors Sunstone Hotel Investors saw a 30.9% increase in sales for its current quarter, and a 30.3% growth for the next.
2. Globus Medical (GMED)
12.6% sales growth and 8.91% return on equity
Globus Medical, Inc., a medical device company, focuses on the development and commercialization of implants that heal patients with musculoskeletal disorders. Its spine product portfolio includes a range of implant and surgical approach options that can be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. In addition, it provides motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures; imaging, navigation, and robotic assisted surgery technology solutions; and hip and knee joint solutions, as well as distributes human cell, tissue, and cellular and tissue based products. Further, the company offers expandable spacer products, which include RISE, RISE-L, CALIBER, CALIBER-L, ALTERA, ELSA, ELSA-ATP, SABLE, MAGNIFY, MAGNIFY-S, FORTIFY, and XPand; CREO thoracolumbar stabilization platform that offers instruments and implants for treating pathologies; CREO MIS and CREO MCS, options designed for less invasive surgery and minimal muscle disruption; CREO Derotation and CREO Rod Link Reducer systems, which help to streamline various derotation maneuvers for deformity correction; CREO Addition that provides a range of connectors; and CREO Fenestrated, a cement augmented pedicle screw system for patients with advanced stage tumors and limited life expectancy, as well as QUARTEX, an occipito-cervico-thoracic stabilization system. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Earnings Per Share
As for profitability, Globus Medical has a trailing twelve months EPS of $1.5.
PE Ratio
Globus Medical has a trailing twelve months price to earnings ratio of 49.24. Meaning, the purchaser of the share is investing $49.24 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.91%.Moving Average
Globus Medical's worth is above its 50-day moving average of $68.96 and way higher than its 200-day moving average of $64.85.3. Yelp (YELP)
11.6% sales growth and 5.74% return on equity
Yelp Inc. is a marketplace that links consumers to local businesses both in the United States as well as internationally. Yelp's platform includes local businesses such as restaurants, shops, beauty, fitness and health. It also covers home, local and auto as well as professional, pet, event, real estate and financial services. Businesses can use the platform to advertise for free or paid. These include multi-location and cost-per click search advertising, and businesses are able to target local audiences with targeted search ads. Other services include Yelp Reservations, which allows users to make reservations online for restaurant, nightlife and other venues from Yelp's business pages. Yelp Waitlist is a subscription-based solution for managing waitlists. It also provides local analytics for business owners and gives them access to historical data. Yelp Fusion offers both free and paid access and data that can be used by enterprises. It also offers content licensing and third-party data providers the ability to manage businesses' listings. The company also offers products through direct sales channels, indirectly through partners, and online via its website. It has non-advertising partnership arrangements as well. Grubhub is a strategic partner of the company, allowing customers to order food for pick-up or delivery. Yelp Inc. is an American company that was founded in 2004. Its headquarters are in San Francisco, California.
Earnings per Share
Yelp's trailing 12 months profit per share was $-0.27
For the 12 trailing months, the company's return-on-equity, which is an indicator of the business' profitability relative to shareholders' equity, was 5.74%.Growth Estimates Quarters
The company's growth estimates for the current quarter is a negative 100% and positive 13% for the next.Sales Growth
Yelp saw a 11.5% increase in sales for its current quarter, and 11.6% the following quarter.
4. Regional Management Corp. (RM)
10% sales growth and 23.76% return on equity
Regional Management Corp. is a consumer finance firm that offers a variety of installment loans to people who have limited credit access from credit cards companies, banks, thrifts and credit card companies. You can get small or large installment loans, retail loans for furniture and appliances as well as insurance products such as credit life, credit accident, health, vehicle single interests, credit involuntary unemployed insurance and collateral protection insurance. Its loans can be sourced via branches, direct mail, digital partners and retailers as well as through its consumer website. It had 366 branches across 11 states in the Southeastern and Mid-Atlantic regions. Regional Management Corp. was established in 1987. It is located in Greer in South Carolina.
Earnings per Share
Regional Management Corp.'s trailing 12-month EPS is $6.93.
PE Ratio
Regional Management Corp.'s trailing 12 months earnings to price ratio is 3.9. The purchaser of the shares is therefore investing $3.9 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 23.76%.Moving Average
Regional Management Corp.'s value is under its 50-day moving average of $29.69 and way under its 200-day moving average of $37.49.5. Amphastar Pharmaceuticals (AMPH)
7.1% sales growth and 16.51% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $1.5.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 18.68. Meaning, the purchaser of the share is investing $18.68 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.51%.Earnings Before Interest, Taxes, Depreciation, and Amortization
Amphastar Pharmaceuticals's EBITDA is 41.97.
Volume
Amphastar Pharmaceuticals' last reported volume is currently 168158, which is 22.7% less than its average volume 217554.
Growth Estimates Quarters
For the current quarter, the company expects to grow by 4.8% and 10.6% respectively.Yearly Top and Bottom Value
Amphastar Pharmaceuticals's stock is valued at $28.02 at 19:22 EST, way below its 52-week high of $44.46 and way higher than its 52-week low of $22.07.
6. Albany International Corporation (AIN)
5.8% sales growth and 12.59% return on equity
Albany International Corp. engages in the textile and materials processing businesses. The company operates in two segments, Machine Clothing (MC) and Albany Engineered Composites (AEC). The MC segment designs, manufactures, and markets paper machine clothing for use in manufacturing papers, paperboards, tissues, and towels. This segment offers forming, pressing, and drying fabrics, as well as process belts. It also provides customized and consumable fabrics that are used in the manufacturing process in the pulp, corrugator, nonwovens, fiber cement, building products, tannery, and textile industries. This segment sells its products directly to end-user customers. The AEC segment designs, develops, and manufactures composite structures primarily to customers in the commercial and defense aerospace industries. The company operates in the United States, Switzerland, France, Brazil, China, Mexico, and internationally. Albany International Corp. was founded in 1895 and is headquartered in Rochester, New Hampshire.
Earnings Per Share
As for profitability, Albany International Corporation has a trailing twelve months EPS of $3.62.
PE Ratio
Albany International Corporation has a trailing twelve months price to earnings ratio of 27.27. Meaning, the purchaser of the share is investing $27.27 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.59%.Volume
Today's last reported volume for Albany International Corporation is 39996 which is 69.29% below its average volume of 130279.
Growth Estimates Quarters
The company's growth estimates for the current quarter is a negative 11.6% and positive 4.4% for the next.Moving Average
Albany International Corporation is worth more than its moving average for 50 days of $97.37, and much higher than its moving average for 200 days of $87.32.Revenue Growth
Year-on-year quarterly revenue growth grew by 12.1%, now sitting on 1.01B for the twelve trailing months.